Kolon Life Science Secures Singapore Patent for TG-C Osteoarthritis Treatment Composition
Securing Cell Size Homogenization Technology
Expanding Patent Portfolio in Asia
Kolon Life Science has secured a manufacturing-related patent for TG-C, a cell and gene therapy for osteoarthritis currently being developed by its affiliate Kolon TissueGene, in Singapore.
Kolon Life Science announced on the 17th that its patent for a “pharmaceutical composition for the prevention or treatment of osteoarthritis” has been approved for registration in Singapore. This patent includes both the composition and manufacturing methods related to the technology that enables the stable acquisition of cells of a certain size during the manufacturing process of TG-C.
TG-C is a cell and gene therapy injected into the knee joint cavity. It is being developed using a method that involves mixing allogeneic cartilage-derived chondrocytes with genetically modified cells into which the TGF-β1 gene has been introduced.
This patented technology includes a manufacturing process that removes cell aggregates formed during cell culture and secures cells within a specific size range. Kolon Life Science explained that, through this technology, it has secured the rights to consistently control cell characteristics during TG-C production.
This patent has already been registered in the United States, Korea, Japan, and Australia, and applications are underway in countries such as China and Canada. Kolon Life Science plans to continue securing rights for the commercialization of TG-C across Asia based on the acquisition of this Singaporean patent.
Lee Hankook, CEO of Kolon Life Science, said, "Our technological competitiveness in stably managing cell quality during TG-C manufacturing is being recognized internationally," adding, "We will continue preparing for global commercialization."
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Kolon TissueGene, the developer of TG-C, is scheduled to announce topline results from its Phase 3 clinical trial in the United States in July. The company will then proceed with preparations for a product approval application to the U.S. Food and Drug Administration (FDA).
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.